| Drug General Information |
| Drug ID |
D04MYT
|
| Former ID |
DNC010678
|
| Drug Name |
4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C10H8N4
|
| Canonical SMILES |
C1=CNC2=NC=CC(=C21)C3=CNN=C3
|
| InChI |
1S/C10H8N4/c1-3-11-10-9(2-4-12-10)8(1)7-5-13-14-6-7/h1-6H,(H,11,12)(H,13,14)
|
| InChIKey |
FATFDRYYCYZBQB-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
mRNA of Aurora B |
Target Info |
Inhibitor |
[1]
|
|---|
| Aurora kinase A |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Oocyte meiosis
|
|
Pathway Interaction Database
|
Aurora B signaling
|
|
Signaling by Aurora kinases
|
|
Aurora C signaling
|
|
FOXM1 transcription factor network
|
|
Aurora A signalingaurora_b_pathway:Aurora B signaling
|
|
Integrin-linked kinase signaling
|
|
PLK1 signaling events
|
|
Aurora A signaling
|
|
Reactome
|
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
|
|
Separation of Sister Chromatids
|
|
Resolution of Sister Chromatid Cohesion
|
|
RHO GTPases Activate Formins
|
|
Mitotic PrometaphaseR-HSA-174178:APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
|
|
Regulation of PLK1 Activity at G2/M Transition
|
|
WikiPathways
|
Mitotic Metaphase and Anaphase
|
|
Mitotic Prometaphase
|
|
Regulation of Microtubule Cytoskeleton
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
APC/C-mediated degradation of cell cycle proteinsWP437:EGF/EGFR Signaling Pathway
|
|
JAK/STAT
|
|
Gastric Cancer Network 1
|
|
Integrated Breast Cancer Pathway
|
|
APC/C-mediated degradation of cell cycle proteins
|
| References |
| REF 1 | Bioorg Med Chem Lett. 2010 Apr 15;20(8):2552-5. Epub 2010 Mar 1.Discovery of a new series of Aurora inhibitors through truncation of GSK1070916. |
|---|
